Ritter Pharmaceuticals (RTTR) Receives Media Impact Rating of 0.14

News headlines about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive on Friday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.5533164883819 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have impacted Accern’s rankings:

Several brokerages have weighed in on RTTR. ValuEngine raised Ritter Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research lowered Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $2.10.

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) remained flat at $$0.30 during mid-day trading on Friday. The stock had a trading volume of 181,285 shares, compared to its average volume of 578,523. Ritter Pharmaceuticals has a 52-week low of $0.18 and a 52-week high of $2.44. The company has a market capitalization of $15.10 and a price-to-earnings ratio of -0.26.

ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/16/ritter-pharmaceuticals-rttr-receives-media-impact-rating-of-0-14.html.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply